Comparing two chemotherapy combinations after pancreatic cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial compares two different chemotherapy combinations given after surgery to lower the chance of pancreatic cancer coming back. One combines a new drug (HR070803) with two standard drugs (oxaliplatin and S-1), and the other uses a standard three-drug regimen (NALIRIFOX).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove pancreatic cancer (the surgeon was able to remove all visible cancer, even if some cancer cells were seen at the edges).
- You are up and about and able to carry out light activities (ECOG score 0 or 1).
- Your doctor expects you to live at least 6 more months.
- You are fully recovered from surgery and plan to start treatment within 3 to 12 weeks after surgery.
- At least 15 lymph nodes were removed during your surgery for examination.
- You have not had chemotherapy or radiation before surgery for this cancer.
- Your CA19-9 blood test result is within the normal range (checked within 14 days before starting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different chemotherapy combinations after surgery for pancreatic cancer. The goal is to see which is better at preventing the cancer from coming back. You would receive either liposomal irinotecan with oxaliplatin and S-1, or gemcitabine with capecitabine.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.